PharmaLex extends footprint for technology-enabled smart services with new strategic partnership

Merger with pharmasol adds pharmacovigilance and business support expertise and diversified customer portfolio


Frankfurt, Germany – 7 December 2021: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced a merger with pharmasol, a leading global life sciences organization focused on pharmacovigilance IT and business support.


Founded in 2001 and with headquarters in Germany, pharmasol provides software and hosting on a subscription basis, as well as pharmacovigilance (PV) services. psiXchange is a state-of-the-art safety letter distribution platform with a highly diversified portfolio of customers spanning leading pharmaceutical and biotech companies and top 10 global CROs.


“The merger with PharmaLex enables us to expand our market reach and provide a deeper pool of strategic advisory and solution consulting expertise for our clients,” said pharmasol CEO and owner Torsten Adam. “Furthermore, the merger provides both organizations with greater depth in the fast-growing and highly competitive area of pharmacovigilance.”


“pharmasol is an excellent fit for PharmaLex, offering strong technical expertise in solving complex and innovative data strategy and governance challenges, a platform that supports full end-to-end business process automation, scalable services and a team with deep technical and PV expertise,” said PharmaLex CEO Dr. Thomas Dobmeyer. “The merger enables us to expand our capabilities with highly talented people and advanced technology, while increasing our technology-enabled smart services footprint with end-to-end business process automation services.”


About PharmaLex <Confidence beyond compliance>:

PharmaLex is a leading provider of specialized services for the pharma, biotech and medtech industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-enabled solutions to support you through the entire product lifecycle. We deliver exceptional results — going above and beyond the standard to deliver tailor-made solutions worldwide.


The PharmaLex Group now has over 1,700 employees, with 45 offices in 24 countries and more than 1,000 satisfied clients worldwide.


For further information, please contact:
Ms. Elizabeth Hunt; PharmaLex GmbH; Manager External Communications
+00 353 86 811 2319
Harrlachweg 6; 68163 Mannheim; Germany

Scroll to Top

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from Should you receive an email and are unsure as to its validity, please report it to

Many thanks for your understanding.

The PharmaLex Team